Association of ApoE and HDL.C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy

Bibliography

• Davignon J: Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler. Thromb. Vasc. Biol. 25(2), 267–269 (2005)
   Google Scholar
• Review of ApoE and its association with atherosclerosis and lipid transport
   Google Scholar
• Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507–537 (2000)
   Google Scholar
• Hime NJ, Drew KJ, Hahn C et al.: Apolipoprotein E enhances hepatic lipasemediated hydrolysis of reconstituted highdensity lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry 43(38), 12306–12314 (2004)
   Google Scholar
• Cohn JS, Tremblay M, Amiot M et al.: Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16(1), 149–159 (1996)
   Google Scholar
• Settasatian N, Barter PJ, Rye KA: Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J. Lipid Res. 49(1), 115–126 (2008)
   Google Scholar
• Haffner SM, Stern MP, Miettinen H et al.: Apolipoprotein E polymorphism and LDL?C size in a biethnic population. Arterioscler. Thromb. Vasc. Biol. 16(9), 1184–1188 (1996)
   Google Scholar
• Wilson PW: Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. Clin. Chem. 41(1), 165–169 (1995)
   Google Scholar
• Morrow JA, Hatters DM, Lu B et al.: Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J. Biol. Chem. 277(52), 50380–50385 (2002)
   Google Scholar
• Walden CC, Hegele RA: Apolipoprotein E in hyperlipidemia. Ann. Intern. Med. 120(12), 1026–1036 (1994)
   Google Scholar
• Zannis VI, Breslow JL, Utermann G et al.: Proposed nomenclature of ApoE isoproteins, ApoE genotypes, and phenotypes. J. Lipid Res. 23(6), 911–914 (1982)
   Google Scholar
• Dong LM, Wilson C, Wardell MR et al.: Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269(35), 22358–22365 (1994)
   Google Scholar
• Steinmetz A, Jakobs C, Motzny S et al.: Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 9(3), 405–411 (1989)
   Google Scholar
• Small BJ, Rosnick CB, Fratiglioni L et al.: Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 19(4), 592–600 (2004)
   Google Scholar
• Cedazo-Minguez A: Apolipoprotein E and Alzheimer’s disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 11(6), 1227–1238 (2007)
   Google Scholar
• Hopkins PC, Huang Y, McGuire JG et al.: Evidence for differential effects of ApoE3 and ApoE4 on HDL?C metabolism. J. Lipid Res. 43(11), 1881–1889 (2002)
   Google Scholar
• Effects of different isoforms of ApoE on HDL?C function
   Google Scholar
• Luc G, Bard JM, Arveiler D et al.: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler. Thromb. 14(9), 1412–1419 (1994)
   Google Scholar
• Wilson PW, Myers RH, Larson MG et al.: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272(21), 1666–1671 (1994)
   Google Scholar
• Wilson PW, Schaefer EJ, Larson MG et al.: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler. Thromb. Vasc. Biol. 16(10), 1250–1255 (1996)
   Google Scholar
• Gerdes LU, Gerdes C, Kervinen K et al.: The apolipoprotein e4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 101(12), 1366–1371 (2000)
   Google Scholar
• de Knijff P, Kaptein A, Boomsma D et al.: Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 90(2–3), 169–174 (1991)
   Google Scholar
• Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and b-amyloid peptides. Nat. Genet. 14(1), 55–61 (1996)
   Google Scholar
• Kohlmeier M, Salomon A, Saupe J et al.: Transport of vitamin K to bone in humans. J. Nutr. 126(Suppl. 4), S1192–S1196 (1996)
   Google Scholar
• Stiefel P, Montilla C, Muniz-Grijalvo O et al.: Apolipoprotein E gene polymorphism is related to metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium–lithium countertransport activity in essential hypertension. Metabolism 50(2), 157–160 (2001)
   Google Scholar
• Kahri J, Soro-Paavonen A, Ehnholm C et al.: ApoE polymorphism is associated with C-reactive protein in low-HDL?C family members and in normolipidemic subjects. Mediators Inflamm. 2006(3), 12587 (2006)
   Google Scholar
• Christidis DS, Liberopoulos EN, Kakafika AI et al.: The effect of apolipoprotein E polymorphism on the response to lipidlowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther. 11(3), 211–221 (2006)
   Google Scholar
• Ordovas JM, Mooser V: The ApoE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13(2), 113–117 (2002)
   Google Scholar
• Perova NV, Metelskaya VA, Bubnova MG et al.: Association of Apo E polymorphism with nutritional and drug-induced changes in lipoproteins. Eur. J. Lab. Med. 1, 6 (1997)
   Google Scholar
• Yamada M: Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J. Atheroscler. Thromb. 4(1), 40–44 (1997)
   Google Scholar
• Haddy N, De Bacquer D, Chemaly MM et al.: The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on interindividual variation in lipid levels: results from Apo Europe. Eur. J. Hum. Genet. 10(12), 841–850 (2002)
   Google Scholar
• Mooijaart SP, Berbee JF, van Heemst D et al.: ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 3(6), e176 (2006)
   Google Scholar
• van den Elzen P, Garg S, Leon L et al.: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437(7060), 906–910 (2005)
   Google Scholar
• Reilly M, Rader DJ: Apolipoprotein E and coronary disease: a puzzling paradox. PLoS Med. 3(6), e258 (2006)
   Google Scholar
• van Vliet P, Mooijaart SP, de Craen AJ et al.: Plasma levels of apolipoprotein E and risk of stroke in old age. Ann. NY Acad. Sci. 1100, 140–147 (2007)
   Google Scholar
• Hahne S, Nordstedt C, Ahlin A et al.: Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer’s disease and healthy controls. Neurosci. Lett. 224(2), 99–102 (1997)
   Google Scholar
• Taddei K, Clarnette R, Gandy SE et al.: Increased plasma apolipoprotein E (ApoE) levels in Alzheimer’s disease. Neurosci. Lett. 223(1), 29–32 (1997)
   Google Scholar
• Merched A, Blain H, Visvikis S et al.: Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer’s disease. J. Neurol. Sci. 145(1), 33–39 (1997)
   Google Scholar
• Slooter AJ, de Knijff P, Hofman A et al.: Serum apolipoprotein E level is not increased in Alzheimer’s disease: the Rotterdam study. Neurosci. Lett. 248(1), 21–24 (1998)
   Google Scholar
• Scacchi R, Gambina G, Ruggeri M et al.: Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer’s disease. Neurosci. Lett. 259(1), 33–36 (1999)
   Google Scholar
• Rensen PC, Schiffelers RM, Versluis AJ et al.: Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol. Pharmacol. 52(3), 445–455 (1997)
   Google Scholar
• Angelin B, Holmquist L, Leijd B et al.: Bile acid metabolism in familial dysbetalipoproteinaemia: studies in subjects with the apolipoprotein E-2/2 phenotype. Eur. J. Clin. Invest. 20(2), 143–149 (1990)
   Google Scholar
• Smit M, de Knijff P, Rosseneu M et al.: Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum. Genet. 80(3), 287–292 (1988)
   Google Scholar
• Utermann G, Pruin N, Steinmetz A: Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin. Genet. 15(1), 63–72 (1979)
   Google Scholar
• Mamotte CD, Sturm M, Foo JI et al.: Comparison of the LDL-receptor binding of VLDL?C and LDL?C from ApoE4 and ApoE3 homozygotes. Am. J. Physiol. 276(3 Pt 1), E553–E557 (1999)
   Google Scholar
• Altenburg M, Arbones-Mainar J, Johnson L et al.: Human LDL?C receptor enhances sequestration of ApoE4 and VLDL?C remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler. Thromb. Vasc. Biol. 28(6), 1104–1110 (2008)
   Google Scholar
• Gregg RE, Zech LA, Schaefer EJ et al.: Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78(3), 815–821 (1986)
   Google Scholar
• Chou CY, Jen WP, Hsieh YH et al.: Structural and functional variations in human apolipoprotein E3 and E4. J. Biol. Chem. 281(19), 13333–13344 (2006)
   Google Scholar
• Heeren J, Grewal T, Laatsch A et al.: Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J. Biol. Chem. 279(53), 55483–55492 (2004)
   Google Scholar
• Heeren J, Beisiegel U, Grewal T: Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(3), 442–448 (2006)
   Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8–15 (1989)
   Google Scholar
• Toth PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol. 96(9A), K50–K58; discussion K34–K35 (2005)
   Google Scholar
• Castelli WP, Garrison RJ, Wilson PW et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256(20), 2835–2838 (1986)
   Google Scholar
• Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583–1592 (2001)
   Google Scholar
• Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285(12), 1585–1591 (2001)
   Google Scholar
• Sacks FM, Tonkin AM, Craven T et al.: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDLcholesterol and triglycerides as risk factors. Circulation 105(12), 1424–1428 (2002)
   Google Scholar
• Assmann G, Gotto AM Jr: HDL?C cholesterol and protective factors in atherosclerosis. Circulation 109(23 Suppl. 1), III8–III14 (2004)
   Google Scholar
• Ansell BJ, Fonarow GC, Fogelman AM: High-density lipoprotein: is it always atheroprotective? Curr. Atheroscler. Rep. 8(5), 405–411 (2006)
   Google Scholar
• Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18(4), 427–434 (2007)
   Google Scholar
• deGoma EM, Leeper NJ, Heidenreich PA: Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 51(1), 49–55 (2008)
   Google Scholar
• Review of epidemiology studies demonstrating a U-shaped association of HDL?C levels and coronary artery disease (CAD)
   Google Scholar
• van der Steeg WA, Holme I, Boekholdt SM et al.: High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 51(6), 634–642 (2008)
   Google Scholar
• Retrospective analysis of two large studies (IDEAL and EPIC-Norfolk) examining the association of HDL?C size and levels with CAD
   Google Scholar
• Tall AR: Plasma cholesteryl ester transfer protein. J. Lipid Res. 34(8), 1255–1274 (1993)
   Google Scholar
• Hirano K, Yamashita S, Matsuzawa Y: Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidol. 11(6), 589–596 (2000)
   Google Scholar
• Barkowski RS, Frishman WH: HDL?C metabolism and CETP inhibition. Cardiol. Rev. 16(3), 154–162 (2008)
   Google Scholar
• Matsuura F, Wang N, Chen W et al.: HDL?C from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an ApoE- and ABCG1-dependent pathway. J. Clin. Invest. 116(5), 1435–1442 (2006)
   Google Scholar
• The different binding capacity of ApoE with cholesterol esters compared with ApoA-I
   Google Scholar
• Zhong S, Sharp DS, Grove JS et al.: Increased coronary heart disease in Japanese–American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL?C levels. J. Clin. Invest. 97(12), 2917–2923 (1996)
   Google Scholar
• Joy T, Hegele RA: Is raising HDL?C a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7(2), 143–155 (2008)
   Google Scholar
• Levy Y: High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovasc. Res. 77(4), 614–615 (2008)
   Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007)
   Google Scholar
• Yamashita S, Maruyama T, Hirano K et al.: Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152(2), 271–285 (2000)
   Google Scholar
• Ishigami M, Yamashita S, Sakai N et al.: Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. 116(2), 257–262 (1994)
   Google Scholar
• Brown ML, Inazu A, Hesler CB et al.: Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342(6248), 448–451 (1989)
   Google Scholar
• Keidar S, Ostlund RE Jr, Schonfeld G: Apolipoprotein E-rich HDL?C in patients with homozygous familial hypercholesterolemia. Atherosclerosis 84(2–3), 155–163 (1990)
   Google Scholar
• Oram JF, Lawn RM: ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42(8), 1173–1179 (2001)
   Google Scholar
• Furbee JW Jr, Francone O, Parks JS: In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL?C receptor and apolipoprotein E knockout mice. J. Lipid Res. 43(3), 428–437 (2002)
   Google Scholar
• von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21(1), 13–27 (2001)
   Google Scholar
• Schmitz G, Assmann G: Isolation of human serum HDL1 by zonal ultracentrifugation. J. Lipid Res. 23(6), 903–910 (1982)
   Google Scholar
• The difference in HDL?C seen with familial hypercholesterolemia (FH) patients
   Google Scholar
• Ashby DT, Rye KA, Clay MA et al.: Factors influencing the ability of HDL?C to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18(9), 1450–1455 (1998)
   Google Scholar
• Kontush A, Chantepie S, Chapman MJ: Small, dense HDL?C particles exert potent protection of atherogenic LDL?C against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23(10), 1881–1888 (2003)
   Google Scholar
• Thuahnai ST, Lund-Katz S, Dhanasekaran P et al.: Scavenger receptor class B type Imediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J. Biol. Chem. 279(13), 12448–12455 (2004)
   Google Scholar
• Barter P, Kastelein J, Nunn A et al.: High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168(2), 195–211 (2003)
   Google Scholar
• Morgan J, Carey C, Lincoff A et al.: High-density lipoprotein subfractions and risk of coronary artery disease. Curr. Atheroscler. Rep. 6(5), 359–365 (2004)
   Google Scholar
• Vaisar T, Pennathur S, Green PS et al.: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117(3), 746–756 (2007)
   Google Scholar
• Meyers CD, Kashyap ML: Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr. Opin. Cardiol. 19(4), 366–373 (2004)
   Google Scholar
• Sharp DS, Burchfiel CM, Rodriguez BL et al.: Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese–Americans. Int. J. Clin. Lab. Res. 30(1), 39–48 (2000)
   Google Scholar
• Eriksson M, Carlson LA, Miettinen TA et al.: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 100(6), 594–598 (1999)
   Google Scholar
• Sirtori CR, Calabresi L, Franceschini G: Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 142(1), 29–40 (1999)
   Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL?C cholesterol. N. Engl. J. Med. 350(15), 1505–1515 (2004)
   Google Scholar
• Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269–276 (2002)
   Google Scholar
• Guerin M, Lassel TS, Le Goff W et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL?C to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20(1), 189–197 (2000)
   Google Scholar
• Carrilho AJ, Medina WL, Nakandakare ER et al.: Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 62(1), 82–88 (1997)
   Google Scholar
• Thomas TR, Smith BK, Donahue OM et al.: Effects of omega-3 fatty acid supplementation and exercise on low-density lipoprotein and high-density lipoprotein subfractions. Metabolism 53(6), 749–754 (2004)
   Google Scholar
• Morgan JM, Capuzzi DM, Baksh RI et al.: Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. 91(12), 1432–1436 (2003)
   Google Scholar
• Syvanne M, Nieminen MS, Frick MH et al.: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL?C cholesterol. Circulation 98(19), 1993–1999 (1998)
   Google Scholar
• Otvos JD, Collins D, Freedman DS et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113(12), 1556–1563 (2006)
   Google Scholar
• Asztalos BF, Batista M, Horvath KV et al.: Change in a1 HDL?C concentration predicts progression in coronary artery stenosis. Arterioscler. Thromb. Vasc. Biol. 23(5), 847–852 (2003)
   Google Scholar
• Koo C, Innerarity TL, Mahley RW: Obligatory role of cholesterol and apolipoprotein E in the formation of large cholesterol-enriched and receptor-active high density lipoproteins. J. Biol. Chem. 260(22), 11934–11943 (1985)
   Google Scholar
• Mahley RW, Innerarity TL, Weisgraber KH et al.: Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro. Am. J. Pathol. 87(1), 205–226 (1977)
   Google Scholar
• Mahley RW, Innerarity TL, Bersot TP et al.: Alterations in human high-density lipoproteins, with or without increased plasma-cholesterol, induced by diets high in cholesterol. Lancet 2(8094), 807–809 (1978)
   Google Scholar
• McGill HC Jr, McMahan CA, Kushwaha RS et al.: Dietary effects on serum lipoproteins of dyslipoproteinemic baboons with high HDL1. Arteriosclerosis 6(6), 651–663 (1986)
   Google Scholar
• Yamashita S, Sprecher DL, Sakai N et al.: Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J. Clin. Invest. 86(3), 688–695 (1990)
   Google Scholar
• Describes the content of ApoE and ApoA-I bound to HDL1 of cholesteryl ester transfer protein-deficient patients
   Google Scholar
• Clark RW, Sutfin TA, Ruggeri RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24(3), 490–497 (2004)
   Google Scholar
• Ha YC, Barter PJ: Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp. Biochem. Physiol. B 71(2), 265–269 (1982)
   Google Scholar
• Innerarity TL, Mahley RW, Weisgraber KH et al.: Apoprotein (E–A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E–A-II) complex. J. Biol. Chem. 253(17), 6289–6295 (1978)
   Google Scholar
• Davidson WS, Silva RA: Apolipoprotein structural organization in high density lipoproteins: belts, bundles, hinges and hairpins. Curr. Opin. Lipidol. 16(3), 295–300 (2005)
   Google Scholar
• Silva RA, Hilliard GM, Li L et al.: A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 44(24), 8600–8607 (2005)
   Google Scholar
• Mahley RW, Huang Y, Weisgraber KH: Putting cholesterol in its place: ApoE and reverse cholesterol transport. J. Clin. Invest. 116(5), 1226–1229 (2006)
   Google Scholar
• Richard BM, Pittman RC: Role of HDL1 in cholesteryl ester uptake in rats. J. Lipid Res. 34(4), 571–579 (1993)
   Google Scholar
• Esteve E, Ricart W, Fernandez-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24(1), 16–31 (2005)
   Google Scholar
• Khovidhunkit W, Shigenaga JK, Moser AH et al.: Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J. Lipid Res. 42(6), 967–975 (2001)
   Google Scholar
• Khovidhunkit W, Duchateau PN, Medzihradszky KF et al.: Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis 176(1), 37–44 (2004)
   Google Scholar
• Coetzee GA, Strachan AF, van der Westhuyzen DR et al.: Serum amyloid Acontaining human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261(21), 9644–9651 (1986)
   Google Scholar
• Liuzzo G, Biasucci LM, Gallimore JR et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331(7), 417–424 (1994)
   Google Scholar
• Kosuge M, Ebina T, Ishikawa T et al.: Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ. J. 71(2), 186–190 (2007)
   Google Scholar
• Cabana VG, Feng N, Reardon CA et al.: Influence of ApoA-I and ApoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J. Lipid Res. 45(2), 317–325 (2004)
   Google Scholar
• Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265(2), 501–523 (1999)
   Google Scholar
• Clifton PM, Mackinnon AM, Barter PJ: Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res. 26(12), 1389–1398 (1985)
   Google Scholar
• Miida T, Yamada T, Yamadera T et al.: Serum amyloid A protein generates pre b 1 high-density lipoprotein from a-migrating high-density lipoprotein. Biochemistry 38(51), 16958–16962 (1999)
   Google Scholar
• Describes the structural changes to HDL?C following the binding of serum amyloid A (SAA)
   Google Scholar
• Miida T, Nakamura Y, Inano K et al.: Pre b1 high-density lipoprotein increases in coronary artery disease. Clin. Chem. 42(12), 1992– 1995 (1996)
   Google Scholar
• Tashiro JOM, Nakamura Y, Miyazaki A et al.: Plasma preb1-HDL?C level is elevated in unstable angina pectoris. Atherosclerosis (2008) (In press)
   Google Scholar
• Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8(1), 1–21 (1988)
   Google Scholar
• Norata GD, Pirillo A, Catapano AL: Modified HDL: biological and physiopathological consequences. Nutr. Metab. Cardiovasc. Dis. 16(5), 371–386 (2006)
   Google Scholar
• Navab M, Berliner JA, Subbanagounder G et al.: HDL?C and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21(4), 481–488 (2001)
   Google Scholar
• Banka CL, Yuan T, de Beer MC et al.: Serum amyloid A (SAA), influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36(5), 1058–1065 (1995)
   Google Scholar
• Kisilevsky R, Subrahmanyan L: Serum amyloid A changes high density lipoprotein’s cellular affinity. A clue to serum amyloid A’s principal function. Lab. Invest. 66(6), 778–785 (1992)
   Google Scholar
• Quan G, Xie C, Dietschy JM et al.: Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res. Dev. Brain Res. 146(1–2), 87–98 (2003)
   Google Scholar
• Roheim PS, Carey M, Forte T et al.: Apolipoproteins in human cerebrospinal fluid. Proc. Natl Acad. Sci. USA 76(9), 4646–4649 (1979)
   Google Scholar
• Pitas RE, Boyles JK, Lee SH et al.: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262(29), 14352–14360 (1987)
   Google Scholar
• Koch S, Donarski N, Goetze K et al.: Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42(7), 1143–1151 (2001)
   Google Scholar
• Guyton JR, Miller SE, Martin ME et al.: Novel large apolipoprotein E-containing lipoproteins of density 1.006–001.060 g/ml in human cerebrospinal fluid. J. Neurochem. 70(3), 1235–1240 (1998)
   Google Scholar
• Yamauchi K, Tozuka M, Hidaka H et al.: Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid: effect of phenotype on the distribution of apolipoprotein E. Clin. Chem. 45(9), 1431–1438 (1999)
   Google Scholar
• Reviews the different apolipoprotein content of CNS HDL
   Google Scholar
• Strittmatter WJ, Bova Hill C: Molecular biology of apolipoprotein E. Curr. Opin. Lipidol. 13(2), 119–123 (2002)
   Google Scholar
• Gong JS, Morita SY, Kobayashi M et al.: Novel action of apolipoprotein E (ApoE), ApoE isoform specifically inhibits lipidparticle- mediated cholesterol release from neurons. Mol. Neurodegener. 2, 9 (2007)
   Google Scholar
• Boyles JK, Pitas RE, Wilson E et al.: Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76(4), 1501–1513 (1985)
   Google Scholar
• Yamauchi K, Tozuka M, Nakabayashi T et al.: Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin. Chem. 45(4), 497–504 (1999)
   Google Scholar
• Carlsson J, Armstrong VW, Reiber H et al.: Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin. Chim. Acta 196(2–3), 167–176 (1991)
   Google Scholar
• Elshourbagy NA, Boguski MS, Liao WS et al.: Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc. Natl Acad. Sci. USA 82(23), 8242–8246 (1985)
   Google Scholar
• Swanson LW, Simmons DM, Hofmann SL et al.: Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc. Natl Acad. Sci. USA 85(24), 9821–9825 (1988)
   Google Scholar
• Irizarry M: Modulation of brain apolipoprotein E levels by the low-density lipoprotein receptor. Neurobiol. Lipids 4(2), (2005)
   Google Scholar
• Mahley RW, Huang Y: Apolipoprotein (apo) E4 and Alzheimer’s disease: unique conformational and biophysical properties of ApoE4 can modulate neuropathology. Acta Neurol. Scand. (Suppl. 185), 8–14 (2006)
   Google Scholar
• Methia N, Andre P, Hafezi-Moghadam A et al.: ApoE deficiency compromises the blood–brain barrier especially after injury. Mol. Med. 7(12), 810–815 (2001)
   Google Scholar
• Cras P, Kawai M, Lowery D et al.: Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl Acad. Sci. USA 88(17), 7552–7556 (1991)
   Google Scholar
• Eckert GP, Kirsch C, Leutz S et al.: Cholesterol modulates amyloid b-peptide’s membrane interactions. Pharmacopsychiatry 36 (Suppl. 2), S136–S143 (2003)
   Google Scholar
• Koudinov AR, Koudinova NV, Kumar A et al.: Biochemical characterization of Alzheimer’s soluble amyloid b protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223(3), 592–597 (1996)
   Google Scholar
• Ladu MJ, Reardon C, Van Eldik L et al.: Lipoproteins in the central nervous system. Ann. NY Acad. Sci. 903, 167–175 (2000)
   Google Scholar
• Nathan BP, Bellosta S, Sanan DA et al.: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264(5160), 850–852 (1994)
   Google Scholar
• Holtzman DM, Pitas RE, Kilbridge J et al.: Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl Acad. Sci. USA 92(21), 9480–9484 (1995)
   Google Scholar
• Buttini M, Akeefe H, Lin C et al.: Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97(2), 207–210 (2000)
   Google Scholar
• Akiyama H, Barger S, Barnum S et al.: Inflammation and Alzheimer’s disease. Neurobiol. Aging 21(3), 383–421 (2000)
   Google Scholar
• Vasto S, Candore G, Duro G et al.: Alzheimer’s disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8(12), 1735–1745 (2007)
   Google Scholar
• Gahtan E, Overmier JB: Inflammatory pathogenesis in Alzheimer’s disease: biological mechanisms and cognitive sequeli. Neurosci. Biobehav. Rev. 23(5), 615–633 (1999)
   Google Scholar
• Liang JS, Sloane JA, Wells JM et al.: Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci. Lett. 225(2), 73–76 (1997)
   Google Scholar
• Nybo M, Olsen H, Jeune B et al.: Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement. Geriatr. Cogn. Disord. 9(3), 126–129 (1998)
   Google Scholar
• Flex A, Pola R, Serricchio M et al.: Polymorphisms of the macrophage inhibitory factor and C-reactive protein genes in subjects with Alzheimer’s dementia. Dement. Geriatr. Cogn. Disord. 18(3–4), 261–264 (2004)
   Google Scholar
• Kindy MS, Yu J, Guo JT et al.: Apolipoprotein serum amyloid a in Alzheimer’s disease. J. Alzheimers Dis. 1(3), 155–167 (1999)
   Google Scholar
• Urieli-Shoval S, Cohen P, Eisenberg S et al.: Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J. Histochem. Cytochem. 46(12), 1377–1384 (1998)
   Google Scholar
• McGeer EG, Yasojima K, Schwab C et al.: The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol. Aging 22(6), 843–848 (2001)
   Google Scholar
• Jenny NS, Arnold AM, Kuller LH et al.: Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 27(2), 352–358 (2007)
   Google Scholar
• Kalaria RN, Kroon SN: Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 186(1), 461–466 (1992)
   Google Scholar
• Miida T, Yamazaki F, Sakurai M et al.: The apolipoprotein E content of HDL?C in cerebro-spinal fluid is higher in children than in adults. Clin. Chem. 45(8 Pt 1), 1294–1296 (1999)
   Google Scholar
• Yamauchi K, Tozuka M, Nakabayashi T et al.: Higher avidity binding of apolipoprotein (E-AII) complex than of apolipoprotein E monomer to b-amyloid. J. Neurosci. Res. 58(2), 301–307 (1999)
   Google Scholar
• Brewer HB Jr, Lux SE, Ronan R et al.: Amino acid sequence of human apoLp-Gln-II (ApoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc. Natl Acad. Sci. USA 69(5), 1304–1308 (1972)
   Google Scholar
• Miida T, Yamada T, Seino U et al.: Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta 1761(4), 424–433 (2006)
   Google Scholar
• Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4(4), 214–225 (2007)
   Google Scholar
• Hobbs HH, Russell DW, Brown MS et al.: The LDL?C receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24, 133–170 (1990)
   Google Scholar
• The inability of ApoE4 to form a complex with ApoA-II increases its susceptibility to SAA-induced dissociation
   Google Scholar
• Streja D, Steiner G, Kwiterovich PO Jr: Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann. Intern. Med. 89(6), 871–880 (1978)
   Google Scholar
• Schonfeld G, Patsch W, Rudel LL et al.: Effects of dietary cholesterol and fatty acids on plasma lipoproteins. J. Clin. Invest. 69(5), 1072–1080 (1982)
   Google Scholar
• Goldberg RB, Fless GM, Baker SG et al.: Abnormalities of high density lipoproteins in homozygous familial hypercholesterolemia. Arteriosclerosis 4(5), 472–478 (1984)
   Google Scholar
• Ishida BY, Frolich J, Fielding CJ: Prebmigrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. J. Lipid Res. 28(7), 778–786 (1987)
   Google Scholar
• Ferrieres J, Lambert J, Lussier-Cacan S et al.: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL?C receptor gene mutation. Circulation 92(3), 290–295 (1995)
   Google Scholar
• Gibson JC, Goldberg RB, Rubinstein A et al.: Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis 7(4), 401–407 (1987)
   Google Scholar
• Assmann G, Schmitz G, Menzel HJ et al.: Apolipoprotein E polymorphism and hyperlipidemia. Clin. Chem. 30(5), 641–643 (1984)
   Google Scholar
• Leren TP, Borresen AL, Berg K et al.: Increased frequency of the apolipoprotein E-4 isoform in male subjects with multifactorial hypercholesterolemia. Clin. Genet. 27(5), 458–462 (1985)
   Google Scholar
• Eto M, Watanabe K, Iwashima Y et al.: Increased frequency of apolipoprotein e4 allele in type II diabetes with hypercholesterolemia. Diabetes 36(11), 1301–1306 (1987)
   Google Scholar
• Wiegman A, Sijbrands EJ, Rodenburg J et al.: The apolipoprotein e4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr. Res. 53(6), 1008–1012 (2003)
   Google Scholar
• Eto M, Watanabe K, Ishii K: Reciprocal effects of apolipoprotein E alleles (e 2 and e4) on plasma lipid levels in normolipidemic subjects. Clin. Genet. 29(6), 477–484 (1986)
   Google Scholar
• Sing CF, Davignon J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37(2), 268–285 (1985)
   Google Scholar
• Eto M, Watanabe K, Chonan N et al.: Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 72(2–3), 123–128 (1988)
   Google Scholar
• de Gennes JL, Touraine R, Maunand B et al.: Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. Bull. Mem. Soc. Med. Hop. Paris 118(15), 1377–1402 (1967)
   Google Scholar
• Bosch T, Wendler T: State of the art of low-density lipoprotein apheresis in the year 2003. Ther. Apher. Dial. 8(2), 76–79 (2004)
   Google Scholar
• Mabuchi H, Koizumi J, Shimizu M et al.: Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDLApheresis Study Group. Am. J. Cardiol. 82(12), 1489–1495 (1998)
   Google Scholar
• Thompson GR: LDL?C apheresis. Atherosclerosis 167(1), 1–13 (2003)
   Google Scholar
• Lund-Katz S, Laplaud PM, Phillips MC et al.: Apolipoprotein B-100 conformation and particle surface charge in human LDL?C subspecies: implication for LDL?C receptor interaction. Biochemistry 37(37), 12867–12874 (1998). 182 Davidson WS, Sparks DL, Lund-Katz S et al.: The molecular basis for the difference in charge between pre-b- and a-migrating high density lipoproteins. J. Biol. Chem. 269(12), 8959–8965 (1994)
   Google Scholar
• Desrumaux C, Athias A, Masson D et al.: Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. J. Lipid Res. 39(1), 131–142 (1998)
   Google Scholar
• Moriarty PM: LDL-apheresis therapy: current therapeutic practice and potential future use. Future Lipidol. 1(3), 10 (2006)
   Google Scholar
• de Ferranti SD, Rifai N: C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc. Pathol. 16(1), 14–21 (2007)
   Google Scholar
• Ridker PM, Rifai N, Rose L et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557–1565 (2002)
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195–2207 (2008)
   Google Scholar
• Kobayashi J, Katsube S, Shimoda M et al.: Single LDL?C apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-lowdensity lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin. Chim. Acta 321(1–2), 107–112 (2002)
   Google Scholar
• Moriarty PM, Gibson CA: Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am. J. Cardiol. 95(10), 1246–1247 (2005)
   Google Scholar
• Moriarty PM, Gibson CA, Shih J et al.: C-reactive protein and other markers of inflammation among patients undergoing HELP LDL?C apheresis. Atherosclerosis 158(2), 495–498 (2001)
   Google Scholar
• Otto C, Geiss HC, Empen K et al.: Long-term reduction of C-reactive protein concentration by regular LDL?C apheresis. Atherosclerosis 174(1), 151–156 (2004)
   Google Scholar
• Wieland E, Schettler V, Armstrong VW: Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis 162(1), 187–191 (2002)
   Google Scholar
• Kaul S, Jayaweera AR: Determinants of microvascular flow. Eur. Heart J. 27(19), 2272–2274 (2006)
   Google Scholar
• Glagov S, Zarins C, Giddens DP et al.: Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch. Pathol. Lab. Med. 112(10), 1018–1031 (1988)
   Google Scholar
• Crowley JP, Metzger J, Assaf A et al.: Low density lipoprotein cholesterol and whole blood viscosity. Ann. Clin. Lab. Sci. 24(6), 533–541 (1994)
   Google Scholar
• Sloop GD, Garber DW: The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin. Sci. (Lond.) 92(5), 473–479 (1997)
   Google Scholar
• Rosenson RS, Shott S, Tangney CC: Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 161(2), 433–439 (2002)
   Google Scholar
• Stamos TD, Rosenson RS: Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 146(1), 161–165 (1999)
   Google Scholar
• Slyper A, Le A, Jurva J et al.: The influence of lipoproteins on whole-blood viscosity at multiple shear rates. Metabolism 54(6), 764–768 (2005)
   Google Scholar
• Ruhenstroth-Bauer G, Mossmer G, Ottl J et al.: Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. Eur. J. Clin. Invest. 17(3), 275–279 (1987)
   Google Scholar
• Rosenson RS, Lowe GD: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140(2), 271–280 (1998)
   Google Scholar
• Grutzmacher P, Landgraf H, Esser R et al.: In vivo rheologic effects of lipid apheresis techniques: comparison of dextran sulfate LDL?C adsorption and heparin induced LDL?C precipitation. ASAIO Trans. 36(3), M327–M330 (1990)
   Google Scholar
• Schmaldienst S, Banyai S, Stulnig TM et al.: Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 151(2), 493–499 (2000)
   Google Scholar
• Richter WO, Jacob BG, Ritter MM et al.: Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metab. Clin. Exp. 42(7), 888–894 (1993)
   Google Scholar
• Parker TS, Gordon BR, Saal SD et al.: Plasma high density lipoprotein is increased in man when low density lipoprotein (LDL) is lowered by LDL-pheresis. Proc. Natl Acad. Sci. USA 83(3), 777–781 (1986)
   Google Scholar
• Hershcovici T, Schechner V, Orlin J et al.: Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J. Clin. Apher. 19(2), 90–97 (2004)
   Google Scholar
• Schechner V, Berliner S, Shapira I et al.: Comparative analysis between dextran sulfate adsorption and direct adsorption of lipoproteins in their capability to reduce erythrocyte adhesiveness/aggregation in the peripheral blood. Ther. Apher. Dial. 8(1), 39–44 (2004)
   Google Scholar
• Jackson RL, Busch SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71(2), 481–539 (1991)
   Google Scholar
• Cheung MC, Albers JJ: Active plasma phospholipid transfer protein is associated with ApoA-I- but not ApoE-containing lipoproteins. J. Lipid Res. 47(6), 1315–1321 (2006)
   Google Scholar
• Ancsin JB, Kisilevsky R: The heparin/ heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274(11), 7172–7181 (1999)
   Google Scholar
• Hamazaki H: Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J. Biol. Chem. 262(4), 1456–1460 (1987)
   Google Scholar
• Palumbo B, Cardinali L, Sinzinger H: LDL-apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb. Res. 97(6), 491–494 (2000)
   Google Scholar
• Kojima S, Harada-Shiba M, Yamamoto A: Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther. Apher. 1(4), 309–313 (1997)
   Google Scholar
• Yoshidome H, Kuriyama M, Fujiyama J et al.: Serum amyloid A and P protein levels are lowered by dextran sulfate cellulose low-density lipoprotein apheresis. Artif. Organs 22(2), 144–148 (1998)
   Google Scholar
• Navab M, Ananthramaiah GM, Reddy ST et al.: The double jeopardy of HDL. Ann. Med. 37(3), 173–178 (2005)
   Google Scholar
• Opole IO, Belmont JM, Kumar A et al.: Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am. J. Cardiol. 100(9), 1416–1418 (2007)
   Google Scholar
• Kawano M, Kuroda Y, Terao M et al.: Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis. Clin. Chim. Acta 318(1–2), 91–95 (2002)
   Google Scholar
• Geiss HC, Bremer S, Barrett PH et al.: In vivo metabolism of LDL?C subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL?C subfractions after LDL?C apheresis. J. Lipid Res. 45(8), 1459–1467 (2004)
   Google Scholar
• Koizumi J, Inazu A, Fujita H et al.: Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis 74(1–2), 1–8 (1988)
   Google Scholar
• Krimbou L, Tremblay M, Davignon J et al.: Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-b1-LpE, pre-b2-LpE, and a-LpE. J. Lipid Res. 38(1), 35–48 (1997)
   Google Scholar
• LDL-apheresis effects on HDL-bound ApoE
   Google Scholar
• Weisgraber KH, Mahley RW: Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J. Lipid Res. 21(3), 316–325 (1980)
   Google Scholar
• Cardin AD, Hirose N, Blankenship DT et al.: Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem. Biophys. Res. Commun. 134(2), 783–789 (1986)
   Google Scholar
• Crawford JG: Alzheimer’s disease risk factors as related to cerebral blood flow. Med. Hypotheses 46(4), 367–377 (1996)
   Google Scholar
• Sun ZW, Zhu YX, Liu HY et al.: Decreased cerebral blood flow velocity in apolipoprotein E e4 allele carriers with mild cognitive impairment. Eur. J. Neurol. 14(2), 150–155 (2007)
   Google Scholar
• Lautenschlager NT, Cox KL, Flicker L et al.: Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300(9), 1027–1037 (2008)
   Google Scholar
• Igarashi K, Tsuji M, Nishimura M et al.: Improvement of endothelium-dependent coronary vasodilation after a single LDL?C apheresis in patients with hypercholesterolemia. J. Clin. Apher. 19(1), 11–16 (2004)
   Google Scholar
• Sato M, Amano I: Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther. Apher. Dial. 7(4), 419–424 (2003)
   Google Scholar
• Kobayashi K, Yamashita K, Tasaki H et al.: Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL?C apheresis. Ther. Apher. Dial. 8(5), 383–389 (2004)
   Google Scholar
• Mellwig KP, Baller D, Gleichmann U et al.: Improvement of coronary vasodilatation capacity through single LDL?C apheresis. Atherosclerosis 139(1), 173–178 (1998)
   Google Scholar
• Pfefferkorn TK, Knuppel HP, Jaeger BR et al.: Increased cerebral CO2 reactivity after heparin-mediated extracorporal LDL?C precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke 30(9), 1802–1806 (1999)
   Google Scholar
• Walzl B, Walzl M, Valetitsch H et al.: Increased cerebral perfusion following reduction of fibrinogen and lipid fractions. Haemostasis 25(3), 137–143 (1995)
   Google Scholar
• Walzl M, Lechner H, Walzl B et al.: Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 24(10), 1447–1451 (1993)
   Google Scholar
• Walzl M, Walzl B, Lechner H: Results of a two-month follow-up after single heparininduced extracorporeal LDL?C precipatation in vascular disease. J. Stroke Cerebrovasc. Dis. 4(3), 4 (1994)
   Google Scholar
• Gibson CA, Paolo AM et al.: Cognitive and emotional functions after rapid cholesterol lowering. Presented at: 111th Annual Convention of the American Psychological Association. Toronto, Canada, 8–12 August (2003)
   Google Scholar
• LDL-apheresis study examining the improvement of whole-brain perfusion in patients with multi-infarct dementia
   Google Scholar
• Mackey RH, Kuller LH, Sutton-Tyrrell K et al.: Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am. J. Cardiol. 90(8A), I71–I76 (2002) 236 Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89–94 (2002)
   Google Scholar
• El Harchaoui K, Arsenault BJ, Franssen R et al.: High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 150(2), 84–93 (2009)
   Google Scholar
• Moriarty PM, Gibson CA: Association between hematological parameters and high-density lipoprotein cholesterol. Curr. Opin. Cardiol. 20(4), 318–323 (2005)
   Google Scholar
• Ullrich H, Kleinjung T, Steffens T et al.: Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. J. Clin. Apher. 19(2), 71–78 (2004)
   Google Scholar
• Balletshofer BM, Stock J, Rittig K et al.: Acute effect of rheopheresis on peripheral endothelial dysfunction in patients suffering from sudden hearing loss. Ther. Apher. Dial. 9(5), 385–390 (2005)
   Google Scholar
• Suckfull M: Fibrinogen and LDL?C apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 360(9348), 1811–1817 (2002)
   Google Scholar
• Kobayashi S, Moriya H, Negishi K et al.: LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J. Clin. Apher. 18(3), 115–119 (2003)
   Google Scholar
• Kobayashi S, Moriya H, Maesato K et al.: LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J. Clin. Apher. 20(4), 239–243 (2005)
   Google Scholar
• Mii S, Mori A, Sakata H et al.: LDL?C apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Angiology 49(3), 175–180 (1998)
   Google Scholar
• Walzl B, Walzl M, Lechner P et al.: Heparin-induced extracorporeal LDL?C precipitation (HELP), a new therapeutic intervention in cerebrovascular diseases and peripheral arterial occlusive disease. Wien. Med. Wochenschr. 143(22), 563–570 (1993)
   Google Scholar
• Muso E, Mune M, Fujii Y et al.: Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL?C apheresis compared with steroid monotherapy. Nephron 89(4), 408–415 (2001)
   Google Scholar
• Nakamura T, Kawagoe Y, Ogawa H et al.: Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am. J. Kidney Dis. 45(1), 48–53 (2005)
   Google Scholar
• Ramunni A, Giancipoli G, Guerriero S et al.: LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy. Ther. Apher. Dial. 9(1), 53–58 (2005)
   Google Scholar
• Friedman DS, O’Colmain BJ, Munoz B et al.: Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564–572 (2004)
   Google Scholar
• Pulido JS: Multicenter prospective, randomized, double-masked, placebocontrolled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans. Am. Ophthalmol. Soc. 100, 85–106; discussion 106–107 (2002)
   Google Scholar
• Wang Y, Walli AK, Schulze A et al.: Heparin-mediated extracorporeal low density lipoprotein precipitatioan as a possible therapeutic approach in preeclampsia. Transfus. Apher. Sci. 35(2), 103–110 (2006).
   Google Scholar